<DOC>
	<DOCNO>NCT01507506</DOCNO>
	<brief_summary>This multi-institutional phase III clinical study interventional type . The trial include 220 patient confirm unifocal glioblastoma period 3 year + 3 year follow . Patients unifocal glioblastoma ( diagnosis confirm histology tumoral biopsy surgical specimen ) meet eligibility criterion randomize one chemoradiotherapy arm : - Conventional arm : 3-dimensional conformational radiotherapy + Temozolomide - Experimental arm : simultaneous-integrated boost intensity-modulated radiotherapy guide magnetic resonance spectroscopic image + Temozolomide The patient monitoring regular standardize . The main objective study improve overall survival patient treat experimental group ( simultaneous integrate boost ) .</brief_summary>
	<brief_title>Phase III Study Comparing 2 Brain Conformational Radiotherapy Combination With Chemotherapy Treatment Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>1 . Patients must unifocal glioblastoma ( grade IV astrocytoma , WHO classification ) . The GBM : Or resectable patient receive curative surgery Or unresectable , large tumor diameter ( contrast enhancement ) must less 5 cm MRI 2 . In case , diagnosis must confirm pathologist . In patient surgery possible , diagnosis confirm biopsy tumor tissue . 3 . Methylation status MGMT gene promoter know 4 . Patients undergone resection receive MRI scan surgery order visualize residual tumor . If , operative report must available . 5 . Surgery biopsy must occur 45 day start radiotherapy . 6. WHO ≤ 2 7 . Age ≥ 18 year 8 . Signed Consent collect specific procedure study 9 . Patient member national insurance scheme 1 . Signs hemorrhage preradiotherapy MRI prevent good spectrometric analysis 2 . Patient multifocal glioblastoma 3 . Tumor locate within 2 cm optic chiasm 4 . Patient leptomeningeal metastasis , 5. patient prone epileptic seizure despite treatment anticonvulsant 6 . Patients receive previous treatment glioblastoma multiforme 7 . Abnormal haematological result inclusion : Neutrophils &lt; 1500/mm3 Bloodplatelets &lt; 100000/mm3 8 . Severe chronic renal insufficiency ( creatinin clearance ≤ 30 ml/min calculate use CockroftGault 's formula 9 . Patient unable follow procedure , visit , examination describe study 10 . Any usual formal indication image examination ( important claustrophobia , pace maker ... ) 11 . Pregnant woman nurse mother participate study . Women childbearing age must negative pregnancy test within 72 hour prior study entry 12 . Men woman childbearing age must use effective contraception study entry throughout study 13 . Any concomitant previous malignant disease within 5 year prior study entry 14 . Any prior systemic chemotherapy within 5 year prior inclusion ( malignant disease medical history ) 15 . Any medical condition make inclusion patient study inappropriate opinion investigator 16 . Patient legal guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Intensity modulate radiation therapy ( IMRT )</keyword>
	<keyword>Magnetic resonance spectroscopic imaging ( MRSI )</keyword>
</DOC>